Kincell is a technology-forward contract development and manufacturing organization (CDMO) formed to streamline analytical development, process development, CMC consulting, and early-stage GMP cell therapy manufacturing. Kincell's initial focus is on manufacturing commercially viable immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK, and CAR-M programs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/26/23 | $36,000,000 |
Kineticos Ventures | undisclosed |
